In Vitro ADME Screening Services for Drug Discovery and Early Development
Discovery Plus™ Screening Suite represents our offerings for drug developers who need to compare drug metabolism and drug-drug interaction (DDI) data between different drug candidates quickly and easily before more rigorous definitive studies designed to stand up to regulatory scrutiny. The Suite includes medium-throughput, non-GLP versions of definitive in vitro drug metabolism and DDI assays for comparison of ADME properties of multiple compounds (during the Lead Optimization stage) or to yield preliminary data for planning definitive metabolism studies.
Moving quickly through drug discovery and development saves you time and money; get data from any of the below Discovery Plus™ Suite offerings more quickly to make risk-based decisions faster and get you through the pipeline more efficiently.
Discovery Plus™ Screening Suite Offerings to Develop Your Compound’s PK Profile
Test systems and study design used to evaluate inhibitory potential vary across types of transporters, and can be viewed in terms of uptake and efflux:
Quick and Easy Medium-Throughput Screening
Discovery Plus™ makes it easy to narrow down your list of lead compounds or get useful preliminary data to better plan your definitive studies for preclinical development. We utilize medium-throughput assay design based on our robust, regulatory submission-quality definitive studies to allow multiple compounds to be screened simultaneously. Our in-house expert scientists generate and review the data to ensure you receive the most reliable screening data in the industry.
Our medium-throughput screening methods make it easy for you to determine which compounds to nominate for lead status and move forward into definitive studies. Discovery Plus™ data are typically ready for you to review within 15 business days from the start date, often sooner depending on parameters.
- Dynamic, reliable data
- Over 25 years of ADME screening expertise
- Quick turnaround